CD62L Expression on T Cells is Decreased in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) and Predicts Response to Therapy with Frontline Nilotinib

Sieghart Sopper,Satu Mustjoki,Angelica Loskog,Bjørn Tore Gjertsen,Ute Mark,Jens Haenig,Nidas Jurjonas,Guenther Gastl,Frank Giles,Andreas Hochhaus,Gert J. Ossenkoppele,Kimmo Porkka,Dominik Wolf

CD62L Expression on T Cells is Decreased in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) and Predicts Response to Therapy with Frontline Nilotinib

2014

Sieghart Sopper
Satu Mustjoki
Angelica Loskog
Bjørn Tore Gjertsen
Ute Mark
Jens Haenig
Nidas Jurjonas
Guenther Gastl
Frank Giles
Andreas Hochhaus
Gert J. Ossenkoppele
Kimmo Porkka
Dominik Wolf

CD62L Expression on T Cells is Decreased in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) and Predicts Response to Therapy with Frontline Nilotinib

Keywords:

Nilotinib
Hematology
Chronic phase chronic myelogenous leukemia
Internal medicine
Cancer research
Medicine
response to therapy
Oncology
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations